Scientists at the University of Southampton have made a significant discovery in efforts to develop a vaccine against Zika, dengue and Hepatitis C viruses that affect millions of people around the world.
In a study published in Science Immunology, researchers have shown that natural killer cells (NK cells), which are a fundamental part of the body’s immune system, can recognise many different viruses including global pathogens such as Zika, dengue and Hepatitis C viruses, through a single receptor called KIR2DS2.
Lead researcher Salim Khakoo, Professor of Hepatology, said the findings are very exciting and could change the way viruses are targeted by vaccines but warned that the research is still at an early stage, and animal studies/clinical trials will be needed to test the findings.
Vaccines work by stimulating the immune response to the coat of proteins on the virus enabling the body to fight off the virus and recognise it in the future. However, the viruses are able to change their coat proteins, helping the virus to evade the antibodies, meaning some viruses can be very hard to vaccinate against.
The Southampton team have shown that this NK cell receptor is able to target a non-variable part of the virus called the NS3 helicase protein, which is essential in making the virus work properly. Unlike other proteins, the NS3 helicase protein does not change, which allows the immune system to grab hold of it and let the NK cells deal with the threat.
Professor Khakoo said: “The NS3 helicase protein could be the key in unlocking the defence of lethal viruses that affect so many people around the world. It is very exciting to discover that other viruses similar to Hepatitis C, such as Zika virus, dengue virus, yellow fever virus, Japanese encephalitis virus and in fact all flaviviruses, contain a region within their NS3 helicase proteins that is recognised by exactly the same KIR2DS2 receptor. We believe that by targeting this NS3 helicase region, we could make a new type of vaccine based upon natural killer cells, which can be used to help protect people from these infections.”
The study, which was funded by the Wellcome Trust and the Medical Research Council, analysed DNA from more than 300 patients exposed to the Hepatitis C virus, which showed that the KIR2DS2 receptor was associated with successfully clearing the virus. The team then identified that the immune system targeted the NS3 helicase protein of this using the receptor and found that it prevented the virus multiplying.
They went on to demonstrate that this same mechanism icould be important for many different viruses for example the Zika and dengue viruses, which also contain a region within their NS3 helicase protein that is recognised by the KIR2DS2 receptor.
The researchers now need to determine whether these KIR2DS2+ NK cells are protective during acute flaviviral infections, and are hoping to develop a vaccine that targets natural killer cells. They believe that a similar process could be used to target cancer.
Professor Khakoo added: “Cancer treatments that use the body’s own immune system are becoming more common. Our findings present a completely new strategy for virus therapeutics which could be easily translated into the field of cancer. The next few years are going to be very exciting in this field.”
The Latest on: Vaccine for viruses
Could there be a human vaccine for the West Nile virus?
on April 25, 2018 at 2:08 pm
In 2016, Cody Hopkins was bit by a mosquito and rushed to Dell Children's Hospital. Doctors did not initially test Hopkins for the West Nile virus until his father -- a veterinary tech -- pointed out his son matched all the symptoms and asked for his son ... […]
FDA accepts Sanofi Pasteur's marketing application for expanded use of flu vaccine
on April 25, 2018 at 10:45 am
The FDA accepts for review Sanofi Pasteur's (SNY +0.6%) supplemental marketing application seeking approval to use the 0.5 mL dose of Fluzone Quadrivalent (influenza vaccine) in children ages six months to 35 months. It is is currently approved for use in ... […]
PaxVax Announces the Initiation of Phase 2b Trial for its Chikungunya Vaccine
on April 25, 2018 at 5:39 am
REDWOOD CITY, Calif., April 25, 2018 /PRNewswire/ -- PaxVax, a leading independent specialty vaccine company, announced today the enrollment of the first patient in its Phase 2b dose-finding trial of the chikungunya virus-like particle (VLP) vaccine ... […]
Kentuckians Requesting Hepatitis A Vaccines
on April 24, 2018 at 1:02 pm
However, they always recommend children get the vaccine, as well as other groups who are at risk for the virus. "Those seem to be people who are homeless, folks who use illicit drugs," he said. People seem to be taking that advice. Reports came out that in ... […]
Did the Polio Vaccine Cause Cancer?
on April 24, 2018 at 12:17 pm
The bottom line: It’s highly unlikely that the lots of polio vaccine contaminated in the ‘50s and ‘60s have caused anyone to develop cancer. Polio, or poliomyelitis, is a disease caused by the poliovirus. About 1 in 200 people who contract the virus ... […]
Flu season is finally ending, but the race to create next year's flu vaccine is just beginning
on April 24, 2018 at 1:51 am
When it comes to infectious diseases, we must always be prepared for the unexpected. From the emergence of HIV/AIDS decades ago to the recent spread of Zika virus across the Americas, we continually see unknown diseases emerge and familiar diseases ... […]
The Vaccine Dilemma: How Experts Weigh Benefits For Many Against Risks for a Few
on April 23, 2018 at 5:18 pm
The Vaccine Calculus In some cases, these decisions aren’t that difficult. A flu shot can trigger Guillain-Barre syndrome, though this adverse event is very rare. But influenza infection can also provoke this disorder, a form of progressive paralysis ... […]
FDA investigating unauthorized herpes vaccine research, report says
on April 23, 2018 at 2:47 pm
Lbachir BenMohamed, a professor and director of the Cellular and Molecular Immunology Laboratory at the University of California, Irvine School of Medicine, is also a herpes virus vaccine researcher and edited a paper authored by Halford and published in ... […]
Public flu vaccination program a success without doctors, Haggie insists
on April 23, 2018 at 2:00 am
The health minister says this flu season's vaccination program was a success because more people got flu shots this year compared with last year, even though the province stopped paying doctors to give them. John Haggie says 20 per cent of people in ... […]
Kenya doesn’t have a flu vaccine policy. Why it needs one for babies
on April 17, 2018 at 6:54 pm
Jeanette Dawa received funding for this research from a) the Consortium for Advanced Research Training in Africa (CARTA). . She is affiliated with the Infectious Diseases Society of Kenya, where she serves as treasurer. The statements made and views ... […]
via Google News and Bing News